Incyte | INCY - Umsatzerlöse

Aktienkurs
96.15
Täglich Wechseln
-1.18 -1.21%
Monatlich
-11.81%
Jährlich
35.82%
Q1 Prognose
98.17




Der Umsatz Veränderung Datum
Acadia Pharmaceuticals USD 284M 5.4M 2025-12
Agenus USD 24.07M 2.77M 2025-03
Agios Pharmaceuticals USD 19.97M 7.07M 2025-12
Alnylam Pharmaceuticals USD 1.1B 150M 2025-12
Amgen USD 9.9B 340M 2025-12
BioCryst Pharmaceuticals USD -86.95M 204.03M 2024-12
Biogen USD 2.28B 250M 2025-12
BioMarin Pharmaceutical USD 875M 99M 2025-12
Bristol-Myers Squibb USD 12.5B 300M 2025-12
Eli Lilly USD 19.3B 1.7B 2025-12
Exelixis USD 598.66M 860K 2025-12
Gilead Sciences USD 7.93B 130M 2025-12
Incyte USD 1.51B 140M 2025-12
Ionis Pharmaceuticals USD 203M 46M 2025-12
MacroGenics USD 72.84M 50.6M 2025-09
Merck USD 16.4B 880M 2025-12
Moderna USD 678M 342M 2025-12
Nektar Therapeutics USD 24.12M 635K 2024-09
Neurocrine Biosciences USD 805.5M 10.6M 2025-12
Novartis USD 13.91B 144M 2025-09
Novartis USD 14.36B 478M 2025-09
Pfizer USD 17.58B 880M 2025-12
PTC Therapeutics USD 164.7M 46.3M 2025-12
Puma Biotechnology USD 80.54M 33.46M 2024-09
Regeneron Pharmaceuticals USD 3.88B 130M 2025-12
Sarepta Therapeutics USD 442.9M 43.5M 2025-12
Ultragenyx Pharmaceutical USD 207M 47M 2025-12
Vertex Pharmaceuticals USD 3.19B 110M 2025-12